Stockreport

Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meeting...

Actinium Pharmaceuticals, Inc. (Delaware)  (ATNM) 
NASDAQ:AMEX Investor Relations: ir.actiniumpharma.com
PDF survival at one and two years compared to control arm patients none of whom survived even one year - Unprecedented 100% BMT access and engraftment in evaluable patient [Read more]